[{"orgOrder":0,"company":"Kindred Biosciences","sponsor":"Dechra Pharmaceuticals Manufacturing","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$43.0 million","newsHeadline":"Kindred Biosciences Announces Mirataz\u00ae (mirtazapine transdermal ointment) Transaction","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kindred Biosciences"},{"orgOrder":0,"company":"PDL BioPharma","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"$4.3 million","newsHeadline":"PDL BioPharma Announces Sale of Kybella\u00ae, Zalviso\u00ae and Coflex\u00ae Royalties to SWK Holdings Corporation","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"PDL BioPharma"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONO Receives a Manufacturing and Marketing Approval of Adlumiz\u00ae, a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Ono Pharmaceutical"},{"orgOrder":0,"company":"Strides Shasun Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives US FDA Approval for Potassium chloride for Oral Solution","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Strides Shasun Limited"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexus Pharmaceuticals Receives FDA Approval for Potassium Chloride in Water for Injection","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Nexus Pharmaceuticals"},{"orgOrder":0,"company":"Gelesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Founded Entity Gelesis Presents Findings on Plenity\u00ae-Induced Weight Loss at the AACE 2021 Annual Virtual Meeting","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Gelesis"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wegovy\u2122 (Semaglutide 2.4 mg), the First and Only Once-Weekly Glp-1 Therapy for Weight Management, Approved in the US","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Novo Nordisk"},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Regent Launches Multrys\u2122 (trace elements injection 4*, USP)","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"American Regent"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Gelesis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Is Pleased to Note Publication in Nature\u2019s Scientific Reports Featuring the Gelesis Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"PureTech Health"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wegovy\u2122 Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wegovy\u2122 Recommended for Approval for The Treatment of Obesity by The European Regulatory Authorities","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Novo Nordisk"},{"orgOrder":0,"company":"PLT Health Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PLT Announces New Clinical Studies that Shed Light on the Non-Stimulant Thermogenic Benefits of Slendacor\u00ae Weight Management Complex","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"PLT Health Solutions"},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Regent Announces the Launch of Selenious Acid Injection, USP in a 12 mcg\/2 mL Single-Dose Vial.","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"American Regent"},{"orgOrder":0,"company":"Anglo-French Drugs and industries","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Completes Acquisition of Brands from Anglo-French","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Anglo-French Drugs and industries"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Eton Pharmaceuticals"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Radicle Science","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed to Supply Rare Cannabinoids to Radicle Science's Radicle Energy Study to Assess the Health Effects of THCV","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"InMed Pharmaceuticals"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children\u2019s Hospital Medical Center (CCHMC) Using CURE\u2019s Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell Tran","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Cure Pharmaceutical"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott to Release Elecare\u00ae Amino Acid-Based Formulas to Help Meet Critical Patient Need","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Abbott Laboratories"},{"orgOrder":0,"company":"Sinopharm","sponsor":"ChromaDex, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen\u00ae into Mainland China","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Sinopharm"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$37.5 million","newsHeadline":"Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Baymedica","sponsor":"InMed Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Baymedica"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Launches IMCIVREE\u00ae (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$4.8 million","upfrontCash":"Undisclosed","newsHeadline":"Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$124.8 million","upfrontCash":"Undisclosed","newsHeadline":"Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"TargEDys","sponsor":"Inoliva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TargEDys and Inoliva Announce They Have Entered a Distribution Partnership to Bring Satylia\u00ae to Turkey","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"TargEDys"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"ChromaDex, Inc"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"ChromaDex, Inc"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Tru Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
Tru Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
Satylia, also called EnteroSatys in other markets, is a precision probiotic with a characterized mechanism of action at molecular level: it increases feelings of fullness thanks to the probiotic's protein ClpB that mimics the satiety hormone alpha-MSH.
Rhythm intends to use the net proceeds from this offering to advance global commercialization of IMCIVREE for obesity due to POMC, PCSK1 or LEPR deficiency and BBS, to advance clinical development of setmelanotide in hypothalamic obesity.
Proceeds will be used to fund the Company’s lead asset, Imcivree (setmelanotide acetate), and support intellectual property development, other commercial activities, and for general working capital purposes.
Imcivree (setmelanotide) also achieved a meaningful reduction in hunger scores. Consistent with prior clinical experience in other rare MC4R pathway diseases, setmelanotide was observed to be generally well tolerated.
IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic POMC.
Rhythm intends to use the proceeds from the Agreement and its cash on hand to support global commercialization efforts for IMCIVREE® (setmelanotide) and ongoing clinical development.
Tru Niagen®, featuring Niagen®, is one of the top-selling brands in the Vitamin B3 category on Amazon U.S. for boosting NAD+ levels. Supplementation with Niagen® is backed by 20 published and peer-reviewed clinical trials.
EleCare formulas are hypoallergenic and are used by infants and children who have severe food allergies or gastrointestinal (GI) disorders that require amino acid-based formulas.
Market Place
Company
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
